Humacyte Stock Fundamentals
| HUMA Stock | USD 4.43 0.15 3.50% |
Humacyte fundamentals help investors to digest information that contributes to Humacyte's financial success or failures. It also enables traders to predict the movement of Humacyte Stock. The fundamental analysis module provides a way to measure Humacyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Humacyte stock.
At present, Humacyte's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 80.4 M, whereas Interest Expense is forecasted to decline to about 1.1 M. Humacyte | Select Account or Indicator |
Humacyte Company Current Valuation Analysis
Humacyte's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Humacyte Current Valuation | 566.7 M |
Most of Humacyte's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Humacyte is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Humacyte Current Valuation Historical Pattern
Today, most investors in Humacyte Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Humacyte's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Humacyte current valuation as a starting point in their analysis.
Humacyte Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Humacyte has a Current Valuation of 566.7 M. This is 96.05% lower than that of the Biotechnology sector and 87.8% lower than that of the Health Care industry. The current valuation for all United States stocks is 96.59% higher than that of the company.
Humacyte Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Humacyte's current stock value. Our valuation model uses many indicators to compare Humacyte value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Humacyte competition to find correlations between indicators driving Humacyte's intrinsic value. More Info.Humacyte is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Humacyte's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Humacyte's earnings, one of the primary drivers of an investment's value.Humacyte Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Humacyte's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Humacyte could also be used in its relative valuation, which is a method of valuing Humacyte by comparing valuation metrics of similar companies.Humacyte is currently under evaluation in current valuation category among its peers.
Humacyte ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Humacyte's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Humacyte's managers, analysts, and investors.Environmental | Governance | Social |
Humacyte Fundamentals
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 566.7 M | ||||
| Shares Outstanding | 128.67 M | ||||
| Shares Owned By Insiders | 26.86 % | ||||
| Shares Owned By Institutions | 30.01 % | ||||
| Number Of Shares Shorted | 17.25 M | ||||
| Price To Earning | 18.04 X | ||||
| Price To Book | 30.28 X | ||||
| Price To Sales | 153.91 X | ||||
| Gross Profit | 1.56 M | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) | ||||
| Cash And Equivalents | 189.04 M | ||||
| Cash Per Share | 1.84 X | ||||
| Total Debt | 58.11 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 17.46 X | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (73.31 M) | ||||
| Short Ratio | 5.41 X | ||||
| Earnings Per Share | (1.34) X | ||||
| Target Price | 13.0 | ||||
| Number Of Employees | 183 | ||||
| Beta | 1.47 | ||||
| Market Capitalization | 570 M | ||||
| Total Asset | 128.22 M | ||||
| Retained Earnings | (537.31 M) | ||||
| Working Capital | 64.83 M | ||||
| Net Asset | 128.22 M |
About Humacyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Humacyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Humacyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Humacyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -2.4 M | -2.2 M | |
| Cost Of Revenue | 76.5 M | 80.4 M | |
| Stock Based Compensation To Revenue | 3.56 | 3.17 | |
| Sales General And Administrative To Revenue | 13.16 | 8.41 | |
| Research And Ddevelopement To Revenue | 36.38 | 27.50 | |
| Capex To Revenue | 0.77 | 0.65 | |
| Revenue Per Share | 0.02 | 0.02 | |
| Ebit Per Revenue | (62.15) | (65.26) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:Check out Humacyte Piotroski F Score and Humacyte Altman Z Score analysis. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Quarterly Revenue Growth (1.00) | Return On Assets (0.53) | Return On Equity (8.51) |
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.